Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

ClinicalTrials.gov ID: NCT04677959

Public ClinicalTrials.gov record NCT04677959. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) in improving asthma control compared to the Standard of Care (SoC) group. The secondary objective is to describe the asthma management actions by investigational center health care providers (iHCPs) for all participants in both groups, to evaluate short-acting beta2 agonist (SABA) usage and the number of SABA-free days in the DS group, to evaluate adherence patterns to maintenance treatment (FS eMDPI) in the DS group, to assess behavioral correlates of responsiveness to digital health technology among participants for all participants in both groups, to evaluate work productivity and activity impairment in asthma participants in both groups, to assess the usability and acceptability of the DS by participants in the DS group and the investigational center personnel, and to evaluate the safety of FS eMDPI and Albuterol eMDPI.

Study identification

NCT ID
NCT04677959
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Enrollment
427 participants

Conditions and interventions

Eligibility (public fields only)

Age range
13 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 16, 2021 (Actual)
Primary completion
Mar 4, 2022 (Actual)
Completion
Mar 10, 2022 (Actual)
Last update posted
Mar 14, 2023

2021 – 2022

United States locations

U.S. sites
46
U.S. states
22
U.S. cities
40
Facility City State ZIP Site status
Teva Investigational Site 14971 Phoenix Arizona 85018 —
Teva Investigational Site 14974 Fountain Valley California 92708 —
Teva Investigational Site 14982 Los Angeles California 90025 —
Teva Investigational Site 14945 San Diego California 92120 —
Teva Investigational Site 14946 San Diego California 92123 —
Teva Investigational Site 14966 Colorado Springs Colorado 80907 —
Teva Investigational Site 14962 Wheat Ridge Colorado 80033 —
Teva Investigational Site 14943 Aventura Florida 33180 —
Teva Investigational Site 14969 Boynton Beach Florida 33472 —
Teva Investigational Site 14978 Cutler Bay Florida 33189 —
Teva Investigational Site 14955 Fort Lauderdale Florida 33308 —
Teva Investigational Site 14984 Hialeah Florida 33012 —
Teva Investigational Site 14979 Hialeah Florida 33016 —
Teva Investigational Site 14953 Miami Florida 33135 —
Teva Investigational Site 14975 Miami Florida 33166-6817 —
Teva Investigational Site 14944 Miami Florida 33173 —
Teva Investigational Site 14970 Miami Florida 33216 —
Teva Investigational Site 14960 Miami Lakes Florida 33014 —
Teva Investigational Site 14981 Sarasota Florida 34239 —
Teva Investigational Site 14951 Tallahassee Florida 32308-4355 —
Teva Investigational Site 14942 Savannah Georgia 31406 —
Teva Investigational Site 14947 Boise Idaho 83706 —
Teva Investigational Site 14961 Glenview Illinois 60026 —
Teva Investigational Site 14972 Springfield Illinois 62704 —
Teva Investigational Site 14950 Lexington Kentucky 40509 —
Teva Investigational Site 14949 Owensboro Kentucky 42301 —
Teva Investigational Site 14976 Bangor Maine 04401 —
Teva Investigational Site 14983 White Marsh Maryland 21162 —
Teva Investigational Site 14964 Farmington Hills Michigan 48336 —
Teva Investigational Site 14990 Bellevue Nebraska 68123-4303 —
Teva Investigational Site 14977 Lincoln Nebraska 68505 —
Teva Investigational Site 14957 Toms River New Jersey 08755 —
Teva Investigational Site 14956 Hollis New York 11423 —
Teva Investigational Site 14954 Gastonia North Carolina 28054 —
Teva Investigational Site 14941 Cincinnati Ohio 45221 —
Teva Investigational Site 14968 Toledo Ohio 43617 —
Teva Investigational Site 14952 Oklahoma City Oklahoma 73120 —
Teva Investigational Site 14958 Oklahoma City Oklahoma 73120 —
Teva Investigational Site 14967 Pittsburgh Pennsylvania 15241 —
Teva Investigational Site 14988 Providence Rhode Island 02906 —
Teva Investigational Site 14989 North Charleston South Carolina 29420 —
Teva Investigational Site 14985 Boerne Texas 78006 —
Teva Investigational Site 14963 Houston Texas 77081 —
Teva Investigational Site 14948 Waco Texas 76712 —
Teva Investigational Site 14987 Draper Utah 84020 —
Teva Investigational Site 14965 Murray Utah 84107 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04677959, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 14, 2023 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04677959 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →